{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:30:11Z","timestamp":1793694611743,"version":"4.5.1"},"reference-count":110,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing, and, in many programs, lymphodepletion. Studies in relapsed or refractory multiple myeloma report deep responses with measurable residual disease negativity after BCMA-directed treatment. Because the administered product is a delivery system, cells are shaped by the host environment, which may complicate interpretation of efficacy and safety. This review summarizes clinical data and defines determinants of response that could be optimized for durable translation. It focuses on multiple myeloma, where clinical experience is most mature, while drawing on autoimmune applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In vivo CAR T-cell therapy is appealing because it removes many of the cumbersome steps of conventional cellular therapy. Yet, because treatment administers a delivery system and the CAR T-cell product is generated within the patient, clinical activity depends on interactions among the delivery system, disease context, and host immune state. Trials would benefit from determining how much of the early benefit reflects CAR T-cell activity itself and how much is shaped by the biological conditions that enable, amplify, or constrain it.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0116","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:10:35Z","timestamp":1790187035000},"page":"863-877","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>In Vivo<\/i>\n                    CAR T-cell Therapy: Determinants of Response and Durability"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2903-9040","authenticated-orcid":false,"given":"Mohamed","family":"Abou-el-Enein","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 1 USC\/CHLA Cell Therapy Program, Children\u2019s Hospital of Los Angeles, , Los Angeles, California."},{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 2 Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, , Los Angeles, California."},{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 3 Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, , Los Angeles, California."},{"id":[{"id":"https:\/\/ror.org\/03taz7m60","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southern California 4 Department of Regulatory and Quality Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, , Los Angeles, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026110303170380100_bib1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303170380100_bib2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"2026110303170380100_bib3","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"CAR T-cell product performance in haematological malignancies before and after marketing authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026110303170380100_bib4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-el-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026110303170380100_bib5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"2026110303170380100_bib6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026110303170380100_bib7","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026110303170380100_bib9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"2026110303170380100_bib10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib11","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"key":"2026110303170380100_bib12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"2026110303170380100_bib13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"2026110303170380100_bib14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"2026110303170380100_bib15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"2026110303170380100_bib16","doi-asserted-by":"publisher","first-page":"e9158","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"key":"2026110303170380100_bib17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"2026110303170380100_bib18","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"2026110303170380100_bib19","doi-asserted-by":"publisher","first-page":"eaal1329","DOI":"10.1126\/sciimmunol.aal1329","article-title":"Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation","volume":"2","author":"Kim","year":"2017","journal-title":"Sci Immunol"},{"key":"2026110303170380100_bib20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"2026110303170380100_bib21","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol Ther"},{"key":"2026110303170380100_bib22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"2026110303170380100_bib23","doi-asserted-by":"publisher","first-page":"100027","DOI":"10.1016\/j.bict.2025.100027","article-title":"In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges","volume":"2","author":"Volta","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"key":"2026110303170380100_bib24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat Med"},{"key":"2026110303170380100_bib25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"issue":"Suppl 2","key":"2026110303170380100_bib26","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2025-lba-1","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"2026110303170380100_bib27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303170380100_bib28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.omtm.2019.11.004","article-title":"Dosing and re-administration of lentiviral vector for in vivo gene therapy in rhesus monkeys and ADA-deficient mice","volume":"16","author":"Carbonaro-Sarracino","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026110303170380100_bib29","doi-asserted-by":"publisher","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026110303170380100_bib30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.15252\/emmm.201708148","article-title":"Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy","volume":"9","author":"Milani","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2026110303170380100_bib31","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/bloodadvances.2020002229","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv"},{"key":"2026110303170380100_bib32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol Ther"},{"issue":"Suppl 1","key":"2026110303170380100_bib33","doi-asserted-by":"publisher","first-page":"1750.1","DOI":"10.1182\/blood-2024-208461","article-title":"A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"key":"2026110303170380100_bib34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"2026110303170380100_bib35","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","volume":"34","author":"Lemgart","year":"2026","journal-title":"Mol Ther"},{"key":"2026110303170380100_bib36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026110303170380100_bib37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"2026110303170380100_bib38","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"2026110303170380100_bib39","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2026110303170380100_bib40","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"2026110303170380100_bib41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2026110303170380100_bib42","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"2026110303170380100_bib43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"2026110303170380100_bib44","doi-asserted-by":"publisher","first-page":"eady6730","DOI":"10.1126\/scitranslmed.ady6730","article-title":"In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy","volume":"18","author":"Nie","year":"2026","journal-title":"Sci Transl Med"},{"key":"2026110303170380100_bib45","volume-title":"Kelonia Therapeutics presents first-in-human data from phase 1 inMMyCAR study of KLN-1010 in vivo BCMA CAR-T therapy at the American Society of Hematology (ASH) 2025 annual meeting [press release]","author":"Kelonia Therapeutics","year":"2025"},{"issue":"Suppl 16","key":"2026110303170380100_bib46","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/jco.2026.44.16_suppl.7509","article-title":"Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM)","volume":"44","author":"Ho","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026110303170380100_bib47","volume-title":"Kelonia Therapeutics presents updated first-in-human data from phase 1 inMMyCAR study of KLN-1010 in vivo BCMA CAR-T therapy at the 2026 American Society of Clinical Oncology (ASCO) annual meeting [press release]","author":"Kelonia Therapeutics","year":"2026"},{"key":"2026110303170380100_bib48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2026110303170380100_bib50","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026110303170380100_bib51","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib52","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"2026110303170380100_bib53","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","article-title":"Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial","volume":"10","author":"Li","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026110303170380100_bib54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2026110303170380100_bib55","first-page":"LB5006","article-title":"First-in-human trial of LB2501, an in vivo CD19\/CD20 dual targeting CAR-T therapy, in relapsed\/refractory B-cell NHL","volume":"10","author":"Qu","year":"2026","journal-title":"HemaSphere"},{"key":"2026110303170380100_bib56","volume-title":"Legend Biotech establishes clinical proof-of-concept for LB2501, a potential first-in-class in vivo CD19\/CD20 dual-targeting CAR-T, in relapsed\/refractory B-cell non-Hodgkin lymphoma [press release]","author":"Legend Biotech","year":"2026"},{"key":"2026110303170380100_bib57","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1056\/NEJMc2603114","article-title":"Lentiviral in vivo CD19 CAR T-cell therapy in neurologic autoimmune disorders","volume":"395","author":"Cheng","year":"2026","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2026110303170380100_bib58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1182\/blood-2025-104","article-title":"In vivo pan CAR therapy utilizing circular RNA for treatment of autoimmune diseases","volume":"146","author":"Soto","year":"2025","journal-title":"Blood"},{"key":"2026110303170380100_bib59","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","article-title":"RNA circularization diminishes immunogenicity and can extend translation duration in vivo","volume":"74","author":"Wesselhoeft","year":"2019","journal-title":"Mol Cell"},{"key":"2026110303170380100_bib60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2026110303170380100_bib61","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood.v98.7.2183","article-title":"Apo2L\/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma","volume":"98","author":"Chen","year":"2001","journal-title":"Blood"},{"key":"2026110303170380100_bib62","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.cdd.4400758","article-title":"Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1","volume":"7","author":"Jourdan","year":"2000","journal-title":"Cell Death Differ"},{"key":"2026110303170380100_bib63","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"key":"2026110303170380100_bib64","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"2026110303170380100_bib65","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1182\/bloodadvances.2023010665","article-title":"Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET\/CT after CD19-directed CAR T-cell therapy","volume":"7","author":"de Boer","year":"2023","journal-title":"Blood Adv"},{"key":"2026110303170380100_bib66","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma","volume":"56","author":"Danylesko","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026110303170380100_bib67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2026110303170380100_bib68","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026110303170380100_bib69","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026110303170380100_bib70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026110303170380100_bib71","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"2026110303170380100_bib72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026110303170380100_bib73","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"2026110303170380100_bib74","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2026110303170380100_bib75","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"2026110303170380100_bib76","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"2026110303170380100_bib77","doi-asserted-by":"publisher","first-page":"eaef4134","DOI":"10.1126\/sciimmunol.aef4134","article-title":"Genomic correlates of clinical CAR T cell activity","volume":"11","author":"Leick","year":"2026","journal-title":"Sci Immunol"},{"key":"2026110303170380100_bib78","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat Cancer"},{"key":"2026110303170380100_bib79","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat Med"},{"key":"2026110303170380100_bib80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"2026110303170380100_bib81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"2026110303170380100_bib82","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"2026110303170380100_bib83","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"2026110303170380100_bib84","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303170380100_bib85","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"2026110303170380100_bib86","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"2026110303170380100_bib87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026110303170380100_bib88","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"2026110303170380100_bib89","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The fate(s) of CAR T-cell therapy: navigating the risks of CAR+ T-cell malignancy","volume":"5","author":"Abou-el-Enein","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026110303170380100_bib90","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026110303170380100_bib91","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026110303170380100_bib92","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303170380100_bib93","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib94","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026110303170380100_bib96","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"key":"2026110303170380100_bib97","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"2026110303170380100_bib98","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026110303170380100_bib99","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"2026110303170380100_bib100","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","article-title":"Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed CAR T-cell therapy","volume":"31","author":"Avigan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026110303170380100_bib101","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"2026110303170380100_bib102","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"2026110303170380100_bib103","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-025-04175-8","article-title":"Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma","volume":"32","author":"Lee","year":"2026","journal-title":"Nat Med"},{"key":"2026110303170380100_bib104","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2026.03.047","article-title":"Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse","volume":"189","author":"Gattinoni","year":"2026","journal-title":"Cell"},{"key":"2026110303170380100_bib105","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026110303170380100_bib106","doi-asserted-by":"publisher","first-page":"e003351","DOI":"10.1136\/jitc-2021-003351","article-title":"Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants","volume":"9","author":"Conde","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026110303170380100_bib107","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2026110303170380100_bib108","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","article-title":"Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma","volume":"5","author":"Rade","year":"2024","journal-title":"Nat Cancer"},{"key":"2026110303170380100_bib109","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026110303170380100_bib110","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0116\/3832525\/bcd-26-0116.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0116\/3836439\/bcd-26-0116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/863\/3844174\/bcd-26-0116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/863\/3844174\/bcd-26-0116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:17:11Z","timestamp":1793693831000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/6\/863\/789638\/In-Vivo-CAR-T-cell-Therapy-Determinants-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":110,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0116","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}